{"schema_version":"secwatch.filing_event.v1","accession":"0001576885-25-000087","form_type":"8-K","ticker":"ABOS","cik":"0001576885","company_name":"Acumen Pharmaceuticals, Inc.","filed_at":"2025-07-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.403131+00:00","generated_at":"2026-05-18T06:29:37.794678+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Acumen Pharma enters Alzheimer's collaboration with JCR; up to $555M in milestones","bullets":["JCR receives upfront payment (undisclosed) plus $9.25M option fee if Acumen exercises right to develop two candidates.","Total milestones up to $555M ($40M development, $515M sales) plus single-digit royalties on sales.","Leverages Acumen's amyloid beta oligomer antibodies and JCR's transferrin-receptor BBB technology for Alzheimer's.","Company expects preclinical data package in early 2026 to support option exercise."],"urls":{"canonical":"https://secwatch.observer/filing/0001576885-25-000087","json":"https://secwatch.observer/filing/0001576885-25-000087.json","markdown":"https://secwatch.observer/filing/0001576885-25-000087.md","text":"https://secwatch.observer/filing/0001576885-25-000087.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1576885/000157688525000087/0001576885-25-000087-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1576885/000157688525000087/abos-20250715.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T06:29:37.794678+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}